Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-controlled double-blind randomized proof-of-concept study of zolpidem in late-stage Parkinson's disease
2017-004297-34Phase 2Completed
- Sponsor
- Aston University
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Zolpidem 5 mg with Placebo (2 arms). Primary endpoint: Motor function (UPDRS). Started Jun 2018; status: completed.
02
Drugs
zolpidem
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2017-004297-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004297-34.